General physical condition compatible with the proposed chemotherapy and surgery
Full recovery from nephrectomy or metastasectomy within  weeks from randomization following surgery
Incomplete recovery from any surgery
The subject intends to undergo treatment with the Gliadel wafer at the time of this surgery or has received the Gliadel wafer <  days from WD (surgery)
No prior chemotherapy or surgery for rectal cancer
Patients must begin treatment as outlined in the protocol within  days of definitive surgery (day of surgery is day ; definitive surgery includes second surgeries to resect residual tumor)
No prior bariatric surgery or planning to undergo this procedure within the next  years after study registration
Patients with microscopic positive margins after definitive surgery
Patients with residual macroscopic disease after surgery
Patient must have received either P/D or EPP and must have recovered from all effects of surgery with adequate wound healing; patients who received radiation therapy (RT) must be registered to step  within  days after discontinuing RT; patients who did not receive RT must be registered to step  within  days after surgery
Microscopic positive margins after definitive surgery\r\n* Note: Patients with microscopically focally positive margins following lumpectomy or mastectomy are not excluded if re-excision is not technically feasible and/or there is no benefit to further surgery based on the extent and location of the positive margin
Subject has received surgery within the last four weeks.
Patients who cannot undergo surgery
All patients who have surgery performed must have a cranial MRI pre-operative and post-operative (should be done within  hours of surgery or within  days following surgery)
Patient has had surgery within seven days prior to the date of informed consent.
Patients for whom surgery would be deemed appropriate rather than radiotherapy
After undergoing surgery, patients may be optimally or sub optimally debulked
Participants who underwent major surgery (including craniotomy) or significant traumatic injury within  days prior to initiating therapy; baseline MRIs for participants who underwent salvage surgery must be obtained within  days of registration (similar to other patients who do not have surgery) and there must be measurable disease
Successful Avatar engraftment from initial surgery or surgery/biopsy of recurrent cancer with successful expansion and treatment outcome of Avatar therapy
Patients must be able (physically, mentally and socially) to complete a series of RT, followed by an observation period of - weeks and undergo surgery.
Subjects may not have a history of rectal surgery or lower gastrointestinal bleed
the desmoid tumor has already recurred after a prior surgery or
Be able to undergo protocol therapy, including necessary surgery.
Patients with a known bacterial infection present at the time of surgery or who received antimicrobial therapy within  days prior to surgery
Completed pre-operative chemo radiotherapy followed by surgery
Did not receive concurrent chemoradiotherapy prior to surgery
Surgical patients must have tumor that needs to be removed/debulked and is accessible for the neurosurgeon; need for surgery must be such that the patient can take drug for at least  days to maximum  days before surgery
Patients must have undergone radiation therapy and surgery as part of their standard of care\r\n* Stratum A: Radiation therapy must have started within  weeks of diagnosis by imaging or surgery, whichever is later\r\n* Stratum B: For subjects undergoing surgery for more extensive resection, radiation therapy should be started within - weeks from surgery\r\n* H.K mutation must have been confirmed in the tumor tissue in a CLIA approved laboratory
Presence of any of the following risk factors after surgery:\r\n* Any positive surgical margin.\r\n* Adenopathy below the clavicles
Patients must have at least  days to recover from all prior treatment, including surgery, chemotherapy, immunotherapies, prior to enrollment on this protocol
Positive margins after definitive surgery
Not eligible for surgery
Subject who has undergone platelet receptor GP IIb/IIIa antagonist therapy less than  hours prior to surgery.
Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients; a minimum of  weeks should elapse between any surgery and treatment on study; however, high-risk pathologic features should be present, such as positive margins, positive lymphadenopathy, perineural or angiolymphatic invasion
Timing of radiation must be according to the IRS protocol upon which the patient is treated within either  days of last chemotherapy or surgery; the clinical characteristics dictate the need for or/and timing of surgery and radiotherapy in relation to the chemotherapy
Subject had surgery (excluding line insertions) within  month of the first dose of study drug or has lingering wound complications.
PRIOR THERAPY OR SURGERY
Platelets > , compatible for surgery
Elective indication for nephron sparing surgery
Recovery of reversible effects of prior surgery (i.e., incisional pain, wound drainage) to grade >= , and at least  weeks from prior surgery to treatment start
Scheduled to undergo chest surgery using either minimally invasive (VATS or robotic-assisted surgery) or open techniques (posterolateral, lateral, or anterior thoracotomy or requiring insertion of an inter-rib spreader/retractor) for a primary thoracic non-infectious indication under general anesthesia.
Substantial recovery from surgery resection
Prior reconstructive pelvic surgery involving mesh for prolapse
Deemed ineligible for surgery by the enrolling physician
Participants may have had any extent of prior surgery and/or chemotherapy
Patients must have consented to surgery with an MSK gynecology (Gyn) surgeon
INCLUSION CRITERIA:\n\n        SONICS STUDY COMPLETERS:\n\n        Completed the final SONICS visit (M) and have demonstrated maintenance of clinical\n        response on a stable Therapeutic Dose of levoketoconazole for at least  weeks prior to\n        study entry.\n\n        ALL OTHERS:\n\n          -  Confirmed newly diagnosed, persistent or recurrent endogenous Cushing's syndrome of\n             any etiology, except secondary to malignancy (including pituitary or adrenal\n             carcinoma).\n\n          -  Elevated mean -hour UFC levels at least .X upper limit of the normative range of\n             the study's central laboratory assay and from a minimum of three measurements from\n             adequately collected urine.\n\n          -  Presence of abnormal values from at least one of these two diagnostic tests:\n\n               -  Abnormal Dexamethasone Suppression Test (DST) OR\n\n               -  Elevated late night salivary cortisol concentrations (at least two measurements)\n                  each greater than the upper limit of the study's central laboratory normative\n                  range\n\n          -  Non-candidates for CS-specific surgery, refuse surgery or surgery will be delayed\n             until after study completion and agree to complete this study prior to surgery.\n\n          -  If post-surgical for CS-specific surgery, then no significant post-operative sequelae\n             remain and the risk of such sequelae is considered negligible.\n\n        EXCLUSION CRITERIA:\n\n        Subjects will be excluded from the study if ANY of the following criteria are met (NOTE:\n        exclusion criteria apply to and must be assessed in both cohorts):\n\n          -  Enrolled in SONICS but have not completed SONICS through Visit M.\n\n          -  Pseudo-Cushing's syndrome based on assessment of the Investigator.\n\n          -  Cyclic Cushing's syndrome with multi-week periods of apparent spontaneous CS\n             remission.\n\n          -  Non-endogenous source of hypercortisolism, including pharmacological corticosteroids\n             or ACTH.\n\n          -  Radiotherapy of any modality directed against the source of hypercortisolism within\n             the last  years.\n\n          -  Treatment with mitotane within  months of enrollment.\n\n          -  History of malignancy, including adrenal or pituitary carcinomas (other than low-risk,\n             well-differentiated carcinomas of thyroid, breast or prostate that are very unlikely\n             to require further treatment in the opinion of the treating physician, or squamous\n             cell or basal cell carcinoma of the skin).\n\n          -  Clinical or radiological signs of compression of the optic chiasm.
Prior biliary bypass surgery
Pituitary surgery within six months
Laser-assisted in situ keratomileusis (LASIK) procedure within the last  year or cataract surgery within the last  months.
Participants with measurable disease that has progressed are eligible if prior surgery or locoregional therapy occurred >  days prior to enrollment
Patients must have measurable lesion(s) and one or more of the following criteria:\r\n* Failure of surgery to control disease (i.e. positive margins or recurrence of HSIL after surgery)\r\n* Multifocal or extensive disease for which surgery would result in major deformity that is not be acceptable to the patient\r\n* Disease for which surgery would have a risk of functional impairment that is not be acceptable to the patient (i.e. involve partial or complete excision of the clitoris, anus, vagina, or urethra)
Subjects undergoing emergency surgery
Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery (radiotherapy, cryotherapy, or high frequency ultrasound are allowed after  months of androgen deprivation therapy); or
Cutaneous HNSCC must not be amenable to local treatment modalities, including surgery and/or radiation
Emergency surgery
Surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement
Patients undergoing prior surgery or laser interstitial thermotherapy are allowed
Patients who underwent surgery for a progressive plexiform neurofibroma will be eligible to enter the study after the surgery, provided the plexiform neurofibroma was incompletely resected and is measurable
Treatment must be initiated >=  days and <  weeks from surgery
Medical indication or subject desire to undergo BC surgery prior to completing at least  days of treatment with ODM-.
Cerebral edema, grade  or greater prior to surgery
Pathologically-confirmed invasive breast cancer; if patients undergo upfront surgery, the pathologic stage must be T-T, N-Na or Na; if patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T-T, N-Na or Na
Be willing to allow use of archival tissue from second-look surgery and primary surgery or biopsy for use in this study
Stage IV disease, if the metastatic sites are not amendable for local therapy (i.e. radiation and/or surgery), and are not candidates for breast surgery will not be eligible
Participant has had at least  weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healing; participants with bowel resections at surgery should begin protocol at least  days after surgery
Any stage, considered candidates for surgery and scheduled for surgery either by robotic or by standard surgical technique
Previous treatment with surgery, radiation, chemotherapy, targeted agents are allowed provided that: \r\n* Chemotherapy/major surgery was administered >  days before the start nivolumab\r\n* Minor surgery, radiation, or any targeted agents were administered >  days before the start of nivolumab
The patients refusal to proceed with curative breast surgery has to be documented by the surgeons and medical oncologists note
Prior surgery to the same levels of spine
If they have not previously had a video assisted thoracoscopic surgery, and they have a free pleural space to allow for a video assisted thoracoscopy surgery (VATS) procedure, then they must be willing to undergo a VATS for adequate histologic staging
Patients had craniotomy and surgery to the brain within  days from the date of SRS
Patients have unresectable MPM or the patient refuses surgery for resectable MPM
Inability to safely delay surgery by  weeks as per surgeons discretion
CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within  weeks prior ( weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >=  week after the procedure
No prior definitive surgery for HNSCC
Subjects who have undergone any recent major surgery must have done so at least  weeks prior to starting therapy with DSb, with the following exceptions: vertebroplasty and/or kyphoplasty, which must have been performed at least  week prior to starting DSb; planned elective surgery unrelated to the subjects diagnosis of multiple myeloma, such as hernia repair, may be allowed, at the discretion of the principle investigator, as long as it was performed at least  weeks prior to starting DSb, and subjects have recovered fully from this procedure
Prior breast surgery which interrupts communication of the ductal systems with the nipple
Patients must begin treatment as outlined in the protocol within  days of definitive surgery (day of surgery is day ; definitive surgery includes last surgery to resect residual tumor)
Patients must begin treatment within  days of definitive surgery (day of surgery is day ; definitive surgery includes repeat surgeries to resect residual tumor)
Patients will be consented prior to the surgical evaluation/cytoreductive surgery; patients must have less than or equal to . cm residual disease at the completion of the secondary surgery to be eligible for the study
Major surgery (includes any surgery that carries significant risk of blood loss, extended periods of general anesthesia, or requires at least an overnight hospital admission) within  days before starting treatment or inadequately healed incision/scar from prior surgery
Prior surgery for this cancer
Status post above elective surgery =<  days after first registration\r\n* Elective surgery is defined as:\r\n** Patient was brought from their home (or normal living environment) to FCCC on the day prior to surgery or the day of the index surgery AND\r\n** Surgery was not scheduled/performed as urgent or emergent
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Not able to receive the vaccination within  weeks following the surgery secondary to a delayed recovery from the surgery
Women must not become pregnant prior to surgery or during the first  months after surgery; women who can become pregnant will be asked to practice an effective form of birth control for up to  months after surgery
History of rectal surgery
Therapy must begin =<  weeks after surgery or biopsy
Before administering liposomal doxorubicin, patients must wait - weeks after surgery
Patients found to have non-gynecologic, uterine, or breast primary at surgery
Perineural invasion (PNI) on transoral robotic surgery (TORS) resection of the primary cancer
Patient is medically unfit for surgery or is deemed surgically unresectable by head and neck (H&N) surgeon within  days prior to enrollment, or patient refusal of surgery
Becomes pregnant before surgery or at any time while on study
Macroscopic residual disease after surgery
The patient is able/eligible to undergo treatment with transoral surgery (transoral laser microsurgery [TOLM] or transoral robotic surgery [TORS]) with or without neck dissection and with or without adjuvant radiation therapy or chemoradiation
It is strongly encouraged that all patients have metallic clips placed in the tumor prior to neoadjuvant therapy in order to facilitate evaluation for microscopic disease at the time of surgery; placement of clips is particularly encouraged for patients being considered for breast conserving surgery
Patients who have had non-biopsy surgery in the last  days
If markers or clips were placed at the time of surgery, patient must be able to start treatment within  weeks after lumpectomy or re-excision for adequate margins.
If markers were not placed at the time of surgery and are needed, patient must have markers placed within  weeks after surgery.
Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy
Patients must begin partial brain radiotherapy and temozolomide chemotherapy no sooner than  weeks and no later than  weeks from the surgery in which pathology was confirmed; if a patient elects to have a second surgery to obtain further resection, they will remain eligible for treatment as long as no treatment has been initiated prior to this surgery; in this case, initiation of treatment must begin within  to  weeks from the last surgery; tissue collection is preferred but not mandatory; patients may have radiotherapy administered at outside facilities; radiotherapy must be given within  days of lapatinib initiation and by external beam to a partial brain field in daily fractions of . Gy, to a planned total dose to the tumor of . Gy; stereotactic radiosurgery and brachytherapy will not be allowed
Subjects with recurrent or progressive glioma who have failed standard therapy with surgery and/or radiation for whom local therapy has been requested by the neuro-oncologist. This treatment will be offered as an option for those patients where neither surgery or repeat radiotherapy is advised by the multidisciplinary team. OR Patients with metastatic brain cancer that has progressed despite prior radiotherapy and local therapy is requested by the oncologist. This treatment will be offered as an option for those patients where surgery is not indicated and discussed with the potential options for repeat radiotherapy or salvage radiosurgery by the multidisciplinary team.
ELIGIBILITY CRITERIA FOR REGISTRATION: subjects undergoing primary debulking surgery must have stage III or IV disease and have undergone surgery to include, at a minimum, removal of the uterus, ovaries and fallopian tubes; these patients may be optimally debulked (less than  cm residual disease) but must have grossly visible macroscopic residual disease OR be suboptimally debulked
Patients with resectable disease will be eligible for participation if, and only if, they have comorbidities precluding surgery or refuse to undergo an operation following a multi-disciplinary discussion involving surgical oncology, medical oncology, and radiation oncology; this discussion will actively involve the patient and reinforce that surgery is the current standard of care for such patients
All patients who have surgery performed must have a cranial MRI pre-operative and post-operative (should be done within  hours of surgery or within  days following surgery)
Patients must have undergone debulking surgery with peritonectomy and have been allowed at least  weeks to recover prior to receiving chemotherapy
The patient must be enrolled and have treatment planning between - days from date of last surgery or last cycle of chemotherapy, and radiation must start within - days of date of last surgery or last cycle of chemotherapy
Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)
Participant is able to undergo surgery (planned lobectomy or wedge resection)\r\n* Specifically, the participant has been or will have been cleared for surgery at the time of enrollment; the surgeon can accept the baseline tests done within  days prior to SBRT to clear the patient for surgery
recent (in the last  month prior to randomization) brain, spinal or ophthalmic surgery
Patients must be deemed to be in adequate health to undergo major surgery (pancreaticoduodenectomy)
interval of ?  days between end of surgery and start of protocol therapy for patients who have undergone surgery for recurrent disease.
Prior areolar or breast surgery which interrupts communication of the ductal systems with the nipple
Plan to begin partial brain radiotherapy within - hours after beginning AQN, and within  days ( weeks) of the surgery, or if surgery cannot be performed, the biopsy that confirms GBM diagnosis. Radiation therapy must be given by external beam to a partial brian field in daily fractions of . Gy, to a planned total dose to the tumor of . Gy over  weeks.
Who have had non-biopsy surgery in the last  days
Standard preoperative evaluation is performed and deemed satisfactory to proceed to surgery as per their treating urologist
Patients must have undergone surgery and must not have had any further treatment following surgery. Patients must have undergone surgery of their glioblastoma (GBM), and must not have had any further treatment following surgery. A minimal interval of  days between the day of surgery and the day of inclusion should be respected; a maximal interval of  days between the day of surgery and the day of inclusion should be respected; the patient should have fully clinically recovered from the surgery. (For stage : radiation with concurrent and adjuvant EDO-S only)
The subject must have a complete removal of the primary HNSCC lesion with negative gross and microscopic margins; documentation of margins by frozen sections at surgery is recommended; patients who have already had surgery and have available banked tumor samples can be enrolled AFTER surgery
Subjects who have undergone major surgery within  days of study day ; vertebroplasty and/or kyphoplasty, which must have been performed at least  week prior to starting AMG- + KRd
Subject has undergone a prior intervention (including pleurodesis, surgery, blood patch, and pneumoperitoneum) or valve placement.
The subject must have received maximal debulking surgery and undergo radiotherapy concomitant with temozolomide (- gray [Gy])
Ibrutinib should be held at least  to  days pre- and post-surgery, depending upon the type of surgery and risk of bleeding
Recent resection of recurrent or progressive tumor allowed as long as at least  weeks have elapsed from date of surgery and the subject has recovered from surgery
Expected communication between ventricles and resection cavity as a result of surgery
Participants must have had prior debulking surgery.
Evaluation of lumbar CSF cytology (cytospin preparation for microscopic evaluation) must be performed either pre-operatively or at least  days after definitive surgery unless contraindicated
Prior significant rectal surgery (hemorrhoidectomy is acceptable)
Previous urethral sling, artificial urinary sphincter or penile prosthesis surgery
Patients who require WBRT or surgery at the time of enrollment
Not likely curable with surgery alone
Patients must be entered between  and  weeks after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction
Participants who undergo primary cytoreductive surgery must be entered between  and  weeks after surgery. Participants undergoing interval surgery must have a tumor sample confirming the histological diagnosis prior to enrollment.
Patients may be optimally or suboptimally debulked after surgery
Not curable by surgery.
Avastin use within  days prior to surgery.
Subject is scheduled for another surgery during the first  months following surgery (not including stoma closure ,placement of port for chemotherapy or ureter stent insertion).
Subject requires additional unrelated anastomosis during the surgery.
Previous TransOral Robotic Surgery (TORS) to the oropharynx
If a second surgery is needed for completion of resection, this should be within  days from the first surgery
Patients should be suitable candidates for surgery and chemotherapy
Has undergone prior surgery at the tumor site or the index tumor has undergone previous surgery or ablation treatment
Expected to have surgery during study period;
Prior rectal surgery preventing insertion of the TRUS probe.
Patients with a history of prior pituitary surgery must be at least  days post-surgery to be eligible for inclusion in this study.
Patients with de novo Cushing's disease can be included only if they are not considered candidates for surgery.
Have significant loss of gastrointestinal organs, except for appendix, due to surgery
Patient has EITHER:\r\n* A Kattan nomogram predicted probability of being disease free  years after surgery of < %, OR\r\n* A Gleason sum >= 
Must have significant residual invasive disease at the time of definitive surgery following preoperative chemotherapy. Significant residual disease is defined at least one of the following:
Pregnant at time of surgery
 Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery;
Subject undergoing cardiothoracic surgery is not allergic to protamine; and
Subject receiving intravenous heparin within  hours before surgery or oral Coumadin within  days before surgery;
Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within  days prior to surgery;
If patients underwent surgery, and chemotherapy is indicated after surgery either as adjuvant or to treat residual disease, study treatment should be initiated within  weeks of surgery
Patient desire to undergo breast surgery
Cleared by the primary medical doctor for surgery
Prior therapy or surgery ( to  weeks depending type)
At least  weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiation
At least  months have elapsed between any prior brain radiotherapy and initiation of study therapy (unless the subject recently underwent surgery for proven or suspected disease recurrence, the histology of the most recent surgery demonstrated recurrent/progressive/persistent malignant glioma, Gliadel wafers were not placed during the most recent surgery, neither convection enhanced delivery nor catheters for infusion of chemotherapy were use during the most recent surgery, and radioactive seeds were not placed during the most recent surgery)
No history of bariatric surgery
Subjects who underwent surgery for a progressive plexiform neurofibroma will be eligible to enter the study after the surgery, provided the plexiform neurofibroma was incompletely resected and is evaluable by volumetric analysis
No contraindications to limb-sparing surgery; patient should be evaluated by a surgeon who specializes in sarcoma resections prior to study enrollment to ensure patient (pt) is a candidate for limb-sparing surgery
Surgery or local prostatic intervention within  weeks of the first dose; in addition, any clinically relevant issues from the surgery must have resolved prior to cycle , day 
COHORT A: Patients with underlying heart conditions who are deemed ineligible for surgery
Surgery: >=  weeks from major surgery; if recent craniotomy, adequate wound healing must be determined by neurosurgical team
Eligible to undergo excisional surgery such as pleurectomy/decortication (P/DC) or any other mesothelioma surgery.
No more than  weeks ( days) may elapse between definitive breast surgery (or the last surgery if additional resection required for breast cancer) and randomization
Must have significant residual invasive disease at the time of definitive surgery following preoperative chemotherapy. Significant residual disease is defined as at least one of the following:
For those participants who do not require radiation, registration must be within  days of surgery.
Margin negative surgery
HNSCC and cSCC cannot be curable by surgery and/or radiation therapy
Undergoing laparoscopic or minimally invasive surgery
Surgery or local prostatic intervention within  days of the first dose; in addition, any clinically relevant issues from the surgery must have resolved prior to enrollment
Presence of any of the following risk factors after surgery:\r\n* Any positive surgical margin\r\n* Adenopathy below the clavicles
Patients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade  prior to registration
Stage III patients must have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery.
Patients where more than one debulking surgery has been performed before randomisation to the study. (Patients who, at the time of diagnosis, are deemed to be unresectable and undergo only a biopsy or oophorectomy but then go on to receive chemotherapy and interval debulking surgery are eligible).
Any surgery (including diagnostic laparoscopy and/or biliary +/- duodenal palliative bypass for inoperable PC) within the  weeks prior to day  of study protocol
Therapy must begin =<  weeks after surgery
Patients may have received Gliadel during surgery
Patient must not have transoral robotic surgery (TORS) for a T or T primary tumor
Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).
Cohort : Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within  weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy)
Surgery within  weeks prior to dosing
Patients expected to get surgery.
Patients are eligible for this trial either at presentation for primary melanoma with concurrent regional nodal and/or in-transit metastasis, or at the time of clinically detected nodal and/or in-transit recurrence; patients must undergo biopsy (punch) or open biopsy (if done as part of a clinically indicated baseline diagnostic procedure) within  days of entry into the study; lymphadenectomy/definitive surgery will be performed after at least  and generally not longer than  weeks of induction HDI-ipilimumab therapy; additional delays for definitive lymphadenectomy/surgery are allowed if clinically indicated while awaiting the resolution of potential adverse events from HDI-ipilimumab therapy
Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult
History of gastrointestinal perforation within  months of randomization, except for gastrointestinal (GI) perforation related to a primary colorectal tumor that has subsequently been fully resected; subjects would be eligible if >=  weeks have elapsed from the time of surgery to start date of chemotherapy on protocol and >=  weeks have elapsed from time of surgery to first dose of bevacizumab; the subject must have recovered from the effects of the surgery (e.g. wound is healed, no active infection, no drains, etc.)
Patients expected to receive the first protocol treatment within  weeks after the comprehensive staging surgery
Subjects with chordomas must be considered to have high risk disease as defined by:\r\n* Local recurrence after surgery alone\r\n* Prior intralesional resections\r\n* Unplanned incomplete resections\r\n* Tumors are unresectable or at best marginally resectable based on locally advanced stage, and\r\n* Patients who decline surgery due to excessive morbidity and would otherwise receive non-operative treatment with radiation and/or medical management if not treated on clinical trial
Patients with a history of atherosclerotic coronary artery disease that required bypass surgery may only be enrolled provided that bypass surgery occurred at least one year prior to enrollment and after consultation with a cardiologist to determine stability of disease
Patients who have undergone major surgery (including open biopsy, thoracotomy, organ resection, exploratory laparotomy, arteriovenous grafts) <  days prior to enrollment will have bevacizumab dosing delayed
Subject has had prior cytoreductive surgery yielding tumor for lysate preparation
Subject has had at least  weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healing; subjects with bowel resections at surgery who enroll in cohort  will begin protocol at least  days after surgery if debulking surgery had comprised of bowel resection or other bowel surgery
Following surgery, the patient must have received external beam radiotherapy (- Gy in  Gy fractions,  days per week) with concomitant cisplatin starting within  weeks of surgery. A brief delay in the initiation of radiotherapy following  weeks post-surgery due to administrative reasons (e.g., start of RT on Mondays) may be permitted by the Medical Monitor. The cumulative dose of cisplatin the subject received must be >  mg/m. Protocol therapy must be initiated within a period of - weeks (- days) following the end of RT.
History of surgery within last  days
Patients must be entered no later than  weeks after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction.
Patients with or with anticipation of invasive procedures as defined below: Major surgical procedure within  days of initiating bevacizumab or major procedures anticipated during the course of the study. This includes, but is not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery.
Patients who have metastatic disease, if the metastatic sites are amendable for local therapy (i.e. radiation and/or surgery), and are candidates for breast surgery will be eligible
For advanced or recurrent mucoepidermal carcinoma (MEC) of the salivary gland, patients must not be candidates for curative surgery or radiotherapy.
prior significant rectal surgery (hemorrhoidectomy is acceptable; rectal resection/fissure repair are excluded);
Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted BCNU-wafers
Patient must be suitable candidates for surgery.
Patients must begin treatment as outlined in the protocol within  days of definitive surgery
Estimated blood loss >  liters during surgery
Patient must have the presence of residual resectable disease for which surgery is clinically indicated, and will be performed at All Childrens Hospital
Subjects with unresectable pancreatic cancer who have had surgery (exploratory laparotomy, biliary, gastrointestinal bypass) are eligible, if the subject has fully recovered from surgery and >=  days has passed since the operation; patients with history of pancreatoduodenectomy are eligible provided that there is radiographically documented disease recurrence
Index vertebra(e) had previous spine surgery including vertebroplasty or kyphoplasty,
Major surgery of the spine in same region as the index vertebra(e) was performed within  months before enrollment,
Requires upper and lower limb surgery that will affect functional outcomes,
For subjects receiving adjuvant therapy only, time between definitive surgery and randomization must be ?  weeks. Definitive surgery may include secondary interventions (e.g. to clear inadequate surgical margins)
Tumor must be surgically resectable and curable with conventional surgery
Interval of at least  weeks after biopsy or open surgery and able to begin study treatment.
Recent resection of recurrent or progressive tumor allowed as long as at least  weeks have elapsed from date of surgery & subject has recovered from surgery
Indication for any possible curative treatment after multidisciplinary assessment (surgery, ablation, transplantation)
Any prior surgery at the proposed treatment site OR any prior surgery involving the cryoablation-treated tumor
SURGERY:
Presence of residual disease on final pathology following surgery will be required for immunotherapy; patients with no residual disease at the time of surgery will be removed
Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult
Any BCC that may require Mohs surgery for definitive control
Subjects who have participated in another investigational study within  days prior to surgery.
Subject needs non-emergency cardiac surgery with cardiopulmonary bypass.
Subject needs emergency surgery.
Use of minimally invasive surgery.
Cardiogenic shock at the time of surgery.
Treatment with Clopidogrel and Ticagrelor within  days before surgery, Prasugrel within  days before surgery, glycoprotein IIb/IIIa receptor blockers within  hours of surgery.
Treatment with new oral anticoagulants (Apixaban, Rivaroxaban, Dabigatran) within  hours before surgery.
surgery, radiation, or immunosuppressants within  days
Patients with a non-melanomatous, in situ malignancy or disease that is completely resectable with surgery may be considered after discussion with the Medical Monitor
After definitive surgery, e.g.
Patients who have received surgery are eligible if surgery is performed within  weeks prior to study initiation.
All known lesions were previously treated with surgery or stereotactic surgery (whole-brain radiation is not allowed unless given after definitive treatment with surgery or stereotactic surgery) AND
History of eye surgery within  months, presence of cataracts or other ocular disorders significantly affecting vision
Patients with no prior therapy are eligible, provided they have metastatic disease that is not curable by surgery
Be candidates for clinical resection but for whom surgery is not urgently indicated (eg, for whom surgery within the next - months is appropriate).
Patients must have had  attempt at optimal debulking surgery.
Has at least one or more intraoperative visible air leak >=  mm following the lung resection surgery
Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult
Patients should NOT have undergone any prior cancer directed surgery (exploration, debulking, etc), with the exception of a minor procedure such as biopsy or cytology specimen
Cardiac valvular surgery or open heart surgery
If a patient has had surgery prior to enrolling on study, an enhanced MRI or CT scan should be done within  hours prior to surgery or at least - weeks after surgery
No evidence of macroscopic disease following surgery
Minimal volume, non-disseminated disease, defined by the following:            \r\n* Residual tumor ? . cm^ confirmed by MRI with contrast imaging within  days after surgery\r\n* No metastatic disease in the head, spine, or cerebrospinal fluid (CSF) confirmed by  both of the following:                \r\n** Enhanced MRI of the spine within  days before surgery OR within  days after surgery\r\n** Negative cytological examination of CSF after surgery, but before study enrollment
Surgery or invasive procedure requiring sutures or staples for closure =<  days prior to registration
Have had prior major rectal surgery (except hemorrhoids).
Extensive pelvic exenteration surgery, surgeries which include partial or total vaginectomy with or without reconstruction; radical vulvectomy with or without remove of clitoris
Women who are currently undergoing or planning to undergo reconstruction surgery during the course of the study; women who have completed reconstruction surgery must be  days from surgery
Patient must consent for the appropriate surgery
Have surgery planned within  months of consent; patients who have previously received surgery are eligible
Patients scheduled for surgery at Josie Robertson Surgery Center (JRSC)
Patients with surgery for osseous metastases are allowed
Is eligible for definitive CRT and not considered for primary surgery based on investigator decision
Revision surgery in women at least  years old with surgically absent breast tissue (previous reconstruction with silicone-filled or saline-filled implants or revision reconstruction requiring expansion surgery prior to surgery for study device implantation, with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm and FlexHD PLIABLE, utilized in a prior surgery to expand tissue for study device placement)
Are planning reconstructive surgery with flap repair during trial and follow-up period
Patient must be willing to receive Nestle IMPACT Advance Recovery for five days prior to planned surgery as well as for  days after surgery
History of prior trauma or orthopedic surgery to the cervical vertebral column/spine
If surgery is likely greater than  hours
Subjects that have had prior breast reduction surgery
Reconstructive surgery
Other conditions may exclude participants from the study (e.g. intractable nausea/emesis, allergic reaction to shake, patient decides not to have surgery, any medical condition that prevents patient from having surgery)
EXCLUSION - STUDY : Undergone surgery in the last - weeks
Surgery or hospitalization within the last month
Patients undergoing penile prosthesis surgery
Prior surgery of the sacrum
Patients taking anti-coagulants or other blood thinning medications prior to surgery during the specified time frames:\r\n* Low molecular weight heparin less than  hours prior to surgery\r\n* Coumadin less than  days prior to surgery\r\n* Plavix and NSAIDs less than  days prior to surgery
Patients on Celebrex less than  hours prior to surgery
Require prone positioning for surgery
Patient has successfully lost % of body weight in the previous  months or has had bariatric surgery
Prior H&N surgery excluding diagnostic procedures, transoral surgery, or non-radical neck dissection
Bone fracture/surgery of an extremity during the preceding  months
Patients undergoing gynecologic surgery via midline vertical laparotomy at University of Wisconsin Hospital and Clinics (UWHC)
Patients who have had prior surgery at the spine level to be treated to include prior cement augmentation, laminectomy, vertebrectomy, tumor debulking, instrumentation
An interval of at least one year, but no more than five years, following the full completion of primary therapy for malignant disease; primary therapy is defined as:\r\n* Surgery plus radiation\r\n* Surgery plus chemotherapy\r\n* Surgery plus trastuzumab\r\n* Surgery plus hormone therapy\r\n** Note: For patients who receive hormone therapy following surgery, the definition of one-year post-completion of therapy is defined by the surgery date; patients who are currently receiving hormone therapy are eligible for enrollment
Treated with chemotherapy and surgery
Recent cholecystectomy, liver resection, or biliary surgery within  months.
Co-morbid disease or incurrent illness such as:\r\n* History of head trauma \r\n* History of nasal surgery other than biopsy (before cancer was diagnosed)\r\n* History of sinus surgery other than biopsy (before cancer was diagnosed)\r\n* Chronic rhinosinusitis with or without polyp \r\n* Pregnancy \r\n* Cognitive dysfunction \r\n* History of brain surgery \r\n* Psychiatric or neurologic diseases interfering with sense of smell \r\n* Congenital disorders of olfactory dysfunction \r\n* Olfactory loss prior to onset of nasopharyngeal carcinoma
Additional surgery at the same time as RC (e.g. nephroureterectomy)
Have surgery planned within  months of consent; patients who have previously received surgery are eligible
Emergency surgery of any type that does not allow for proper time for protocol review by the patient
Surgery that involves known/anticipated resection of anterior abdominal wall with plastic surgery reconstruction
Serum creatinine < . measured within  days of surgery
The patient is undergoing Mohs surgery
The patient is not indicated for Mohs surgery
Prior therapy:\r\n* Patients who have undergone  previous surgery for tibial pseudarthrosis repair will be eligible to enter the study if they have refracture; use of BMP- in the prior surgery is permitted, however patients with prior exposure must be screened for antibodies to BMP-, bovine collagen, and rhBMP- neutralizing antibodies; prior use of BMP- is allowed but will be recorded as a possible compounding factor\r\n* Patients who have had  or more prior surgeries for pseudarthrosis repair are ineligible
Positive antibody titers to BMP-, bovine collagen, or BMP- neutralizing antibodies prior to surgery
Participants may have had prior breast surgery and/or chemotherapy
Patients who have not undergone surgery in the past  months; patients may have had neoadjuvant chemotherapy prior to surgery
All women, undergoing surgery, via a midline laparotomy
Benign or oncologic indications for surgery
Surgery will be supervised by one of the gynecologic oncology attendings at Washington University School of Medicine
Open laparotomy or laparoscopic surgery undertaken with cancer therapeutic intent (not a subsequent surgery to manage a postoperative complication) that had occurred =<  days prior to registration and that entailed more than a simple hysterectomy
Patients participating in a meditation practice more often than  hour per week prior to surgery and/or chemotherapy administration
Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within  months prior to registration
Sphincter-preserving surgery and >=  months after restoration of bowel continuity
Prior sacral/lower spinal surgery
Subjects will include women who are being seen at the Women's Health Center by the Gynecological Oncology group at the University of Minnesota (UMMC). These women will be considered for inclusion based on their projected surgery: exploratory laparotomy. Subjects will have to have their surgery at the UMMC within  month of their clinic visit. Patients may be undergoing surgery for either known cancer (ovarian or uterine) or high suspicion for malignancy.
if they are currently using or planning on using other complementary alternative medicine (CAM) therapies prior to or after surgery.
At least  weeks since formal exploratory thoracotomy and patient has recovered from surgery, or  week from diagnostic thoracoscopy
Prior extensive pelvic surgery such as low anterior resection, abdomino-perineal resection, or proctocolectomy continent stool pouch, or any other extensive abdomino-pelvic surgery that would render the patient high-risk for complications as deemed by the surgeon
Demonstrated intra-operative anastomotic leakage when irrigated with  mL of normal saline at the end of surgery
Contraindicated for surgery.
Prolonged chest infection, defined as lung consolidation that requires hospitalization and greater than  days of antibiotics  days prior to surgery.
>  weeks removed from surgery to treat endometrial cancer
Patients must have stage I-III colon or rectal cancer and have undergone definitive therapy; definitive therapy may have included surgery alone, or surgery plus neoadjuvant and/or adjuvant therapy
Previous surgery for cataracts in both eyes, current diagnosis of cataracts, cataracts surgery foreseen in the near future, or ocular disease leading to visual loss
Patients with any breast surgery or biopsy within  days prior to the study
Patients with any breast surgery or biopsy within  days prior to the study
Medical comorbidities making surgery unsafe as determined by the patient's surgeon
Safe for surgery per treating neurosurgeon
Individuals with prior bariatric surgery procedures
Any prior surgery to the prostate within  days of baseline procedures; NOTE: Biopsies are not considered surgeries
Inclusion Criteria:\n\n          . Scheduled to undergo elective colon and/or rectal surgical procedures involving open\n             laparotomy, hand-assisted laparoscopy, and laparoscopic-assisted approaches. The\n             principal incision must have a length of >  cm and <  cm in length.  Eligible\n             surgeries are: left hemicolectomy, right hemicolectomy, transverse colectomy,\n             ileocolic resection, total abdominal colectomy with ileorectal anastomosis, total\n             abdominal proctocolectomy (portion of specimen to be extracted via laparotomy), low\n             anterior resection, sigmoid resection, non-emergent Hartmann procedure, colostomy\n             takedown through laparotomy (not peristomal) incision, ileo-pouch anal anastomosis,\n             and abdominal perineal resection of the rectum.\n\n          . Able to give informed consent.\n\n          . Male or female ? years of age.\n\n          . If female, is non-pregnant (negative pregnancy test result at the\n             Screening/Randomization Visit) and non-lactating.\n\n          . If female, is either not of childbearing potential (defined as postmenopausal for at\n             least  year or surgically sterile [status post bilateral tubal occlusion, bilateral\n             oophorectomy, or hysterectomy]) or practicing  of the following methods of birth\n             control and agrees to continue with this regimen over the study surveillance period:\n\n               -  Oral, implantable, or injectable contraceptives for  consecutive months before\n                  the Baseline/Randomization Visit\n\n               -  Intrauterine device\n\n               -  Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or\n                  cream)\n\n               -  Not sexually-active. Agreement to be available for evaluation at the study site\n                  for scheduled visits.\n\n        Exclusion Criteria:\n\n          . Hypersensitivity to porcine products.\n\n          . History of known anti-myeloperoxidase autoantibodies (i.e., pANCA), as well as\n             patients with known idiopathic necrotizing glomerulonephritis and certain systemic\n             vasculitis conditions [e.g., microscopic polyangiitis of small blood vessels,\n             Wegener's granulomatosis, and Churg-Strauss Syndrome]).\n\n          . Use of microbial sealant (IntegusealTM), any antibiotic-embedded suture, or any\n             antimicrobial-embedded suture to close the principal incision or any suture in the\n             surgical field that has not been formally approved by the relevant local national\n             regulatory authority.\n\n          . Absolute contraindication to general anesthesia.\n\n          . Hypersensitivity reactions to steri-strip tapes, medical-surgery tapes, adhesives, or\n             sutures. (Note: If there can be assurances that the subject will not be exposed to\n             these materials that cause hypersensitivity, alternatives will be allowed.)\n\n          . History of keloid or hypertrophic scarring within or near an incision from a prior\n             surgery.\n\n          . Body mass index [BMI]: >  or <  (both due to the extremely high risk of poor\n             wound healing).\n\n          . ASA score > .\n\n          . Undergoing emergency colorectal surgery such that standard bowel preparation and\n             other standard preoperative precautions and assessments cannot be performed in time\n             before the index-surgery.\n\n         . The planned index-surgery involves removal or placement of mesh (either synthetic or\n             biological) as part of closure in the principal incision or traversing any part of a\n             pre-existing mesh (either synthetic or biological) in the principal incision.\n\n         . There are clinical signs of overt infection necessitating systemic antibiotics via\n             oral, intramuscular, or intravenous routes (e.g., infection of the abdominal wall,\n             peritonitis, pneumonia, and sepsis/septic shock) prior to the index-surgery.\n\n         . Preoperative severe neutropenia (total neutrophil count ? X /L).  (Note:\n             Testing should be performed at the local laboratory.)\n\n         . Receiving any oral or intravenous antibiotics within  hours prior to the\n             index-surgery. (Note: It is permissible to administer conventional oral prophylactic\n             antibiotics as bowel preparation up to the time of the index- surgical procedure, as\n             well as intravenous or intramuscular prophylactic antibiotics just prior to the\n             index-surgery as per the treating surgeon's standard of care.)\n\n         . Preoperative evaluation that the intra-abdominal process might preclude full closure\n             of the skin incision due to severe or morbid obesity (i.e., any mechanical reason\n             that would prevent/preclude primary intent wound healing) at the principal in
Inclusion Criteria:\n\n          . Scheduled to undergo elective colon and/or rectal surgical procedures involving open\n             laparotomy, hand-assisted laparoscopy, and laparoscopic-assisted approaches. The\n             principal incision must have a length of >  cm and <  cm in length.  Eligible\n             surgeries are: left hemicolectomy, right hemicolectomy, transverse colectomy,\n             ileocolic resection, total abdominal colectomy with ileorectal anastomosis, total\n             abdominal proctocolectomy (portion of specimen to be extracted via laparotomy), low\n             anterior resection, sigmoid resection, non-emergent Hartmann procedure, colostomy\n             takedown through laparotomy (not peristomal) incision, ileo-pouch anal anastomosis,\n             and abdominal perineal resection of the rectum.\n\n          . Able to give informed consent.\n\n          . Male or female ? years of age.\n\n          . If female, is non-pregnant (negative pregnancy test result at the\n             Screening/Randomization Visit) and non-lactating.\n\n          . If female, is either not of childbearing potential (defined as postmenopausal for at\n             least  year or surgically sterile [status post bilateral tubal occlusion, bilateral\n             oophorectomy, or hysterectomy]) or practicing  of the following methods of birth\n             control and agrees to continue with this regimen over the study surveillance period:\n\n               -  Oral, implantable, or injectable contraceptives for  consecutive months before\n                  the Baseline/Randomization Visit\n\n               -  Intrauterine device\n\n               -  Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or\n                  cream)\n\n               -  Not sexually-active. Agreement to be available for evaluation at the study site\n                  for scheduled visits.\n\n        Exclusion Criteria:\n\n          . Hypersensitivity to porcine products.\n\n          . History of known anti-myeloperoxidase autoantibodies (i.e., pANCA), as well as\n             patients with known idiopathic necrotizing glomerulonephritis and certain systemic\n             vasculitis conditions [e.g., microscopic polyangiitis of small blood vessels,\n             Wegener's granulomatosis, and Churg-Strauss Syndrome]).\n\n          . Use of microbial sealant (IntegusealTM), any antibiotic-embedded suture, or any\n             antimicrobial-embedded suture to close the principal incision or any suture in the\n             surgical field that has not been formally approved by the relevant local national\n             regulatory authority.\n\n          . Absolute contraindication to general anesthesia.\n\n          . Hypersensitivity reactions to steri-strip tapes, medical-surgery tapes, adhesives, or\n             sutures. (Note: If there can be assurances that the subject will not be exposed to\n             these materials that cause hypersensitivity, alternatives will be allowed.)\n\n          . History of keloid or hypertrophic scarring within or near an incision from a prior\n             surgery.\n\n          . Body mass index [BMI]: >  or <  (both due to the extremely high risk of poor\n             wound healing).\n\n          . ASA score > .\n\n          . Undergoing emergency colorectal surgery such that standard bowel preparation and\n             other standard preoperative precautions and assessments cannot be performed in time\n             before the index-surgery.\n\n         . The planned index-surgery involves removal or placement of mesh (either synthetic or\n             biological) as part of closure in the principal incision or traversing any part of a\n             pre-existing mesh (either synthetic or biological) in the principal incision.\n\n         . There are clinical signs of overt infection necessitating systemic antibiotics via\n             oral, intramuscular, or intravenous routes (e.g., infection of the abdominal wall,\n             peritonitis, pneumonia, and sepsis/septic shock) prior to the index-surgery.\n\n         . Preoperative severe neutropenia (total neutrophil count ? X /L).  (Note:\n             Testing should be performed at the local laboratory.)\n\n         . Receiving any oral or intravenous antibiotics within  hours prior to the\n             index-surgery. (Note: It is permissible to administer conventional oral prophylactic\n             antibiotics as bowel preparation up to the time of the index- surgical procedure, as\n             well as intravenous or intramuscular prophylactic antibiotics just prior to the\n             index-surgery as per the treating surgeon's standard of care.)\n\n         . Preoperative evaluation that the intra-abdominal process might preclude full closure\n             of the skin incision due to severe or morbid obesity (i.e., any mechanical reason\n             that would prevent/preclude primary intent wound healing) at the principal in
Participants with fundoplication within the past year, bariatric surgery or any other major upper gastrointestinal (GI) surgery; fundoplication more than one year ago will not be grounds for exclusion; cholecystectomy will not be grounds for exclusion
Individuals with a history of bariatric surgery or planned bariatric surgery within  years
Subjects who have undergone bariatric surgery are not eligible
Maximum -week interval from last chemotherapy administration or last breast surgery (whichever is more recent) to radiation
Medical comorbidities making surgery unsafe as determined by the patients surgeon
History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery; exception: prior appendectomy is not an exclusion criterion
Definitive surgery being performed at MSKCC within - days of completing NAC
Patients who are cleared for surgery
History of active anal disease requiring surgery
Operated for debulking, decompression or separation surgery
Indications for stress testing is either: \r\n* As part of a pre-operative evaluation prior to a planned cancer related surgery that is considered to be at least of intermediate risk (Intra-peritoneal, intra-thoracic, head and neck surgery, orthopedic or prostate surgery) OR \r\n* As an evaluation in the cardiology clinic for symptoms described in a cardiology consult as typical angina, or of significant suspicion for coronary disease or symptoms described as likely of a cardiac/coronary etiology
Prior anti-incontinence surgery
Subjects expecting to undergo surgery between the imaging sessions; subjects may undergo surgery at any time before the first, or after the last imaging session; this exclusion only applies to each study visit ( day scanning session), and does not apply to the time (at least  weeks) between each study visit
Will undergo surgery or chemo-radiation treatment
Subjects on whom conization, LEEP, cervical laser surgery, or cryosurgery has been performed since enrollment into the BDS-USHPV study
Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy)
Patient desire to undergo breast surgery
Prior resection surgery is allowable.
Patients must be deemed to be eligible candidates for either surgery or stereotactic radiation
Patients who have undergone surgery within  hours prior to the study sonographic examination
Patients not receiving breast surgery care from the Department of Breast Surgery at Columbia Medical Center
No recent chemotherapy or surgery, as defined as in the last  months
Patients who have undergone surgery within  hours prior to the study sonographic examination
Be contraindicated for surgery
Attempted maximal cytoreductive surgery; patients will still be eligible whether optimal or suboptimally debulked at the completion of the surgery
Patients must not have signs of bowel perforation necessitating surgery or acute abdomen evidenced by peritonitis on physical exam within  days prior to registration
Being treated with definitive chemoradiotherapy or surgery
Patient opted for robotic (da Vinci robot) or laparoscopic surgery
Undergoing a second lumpectomy procedure because of positive margins in a previous surgery prior to entering this study.
Timing of surgery: Must be anticipated to take place at least  hour after BLZ- administration
Patients who require surgery sooner than  days from enrollment
Subjects undergoing a second surgery because they had positive margins in a previous surgery.
Women who have declined or otherwise not received preceding surgery
Women with positive margins after primary surgery